TITAN BIOTECH LTD.

Titan Biotech Ltd has filed an intimation regarding the loss of share certificates by a shareholder, Dhiren B Sanghvi Jt. Prashant K Shah. The lost shares, totaling 300, were previously transferred to the Investor Education and Protection Fund (IEPF). The company, through its Registrar and Share Transfer Agent, Beetal Financial & Computer Services Pvt. Ltd., has released an advertisement on June 25, 2026, for the lost shares. Any objections with supporting documents must be submitted within 15 days, after which duplicate shares will be issued via IEPF.

Titan Biotech Ltd has announced the closure of its trading window for all directors, promoters, KMPs, designated employees, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The date of the board meeting to approve these results will be communicated later.

Titan Biotech Ltd has re-appointed M/s Sanjay Kumar Garg & Associates as the Cost Auditor for the financial year 2026-2027, subject to shareholder ratification at the upcoming AGM. The re-appointment was approved by the Board of Directors on May 30, 2026, based on the Audit Committee's recommendation. Mr. Sanjay Kumar Garg has over 24 years of experience in costing, taxation, and auditing.

Titan Biotech Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026, on May 30, 2026. The board has recommended a dividend of ₹0.50 per equity share, subject to shareholder approval. Additionally, the re-appointment of M/s Sanjay Kumar Garg & Associates as Cost Auditor was approved, pending shareholder ratification of remuneration. Mr. Pankaj Kumar Gupta was appointed as the Scrutinizer for the upcoming Annual General Meeting.

The Board of Directors of Titan Biotech Ltd has recommended a dividend of ₹0.50 per equity share, subject to shareholder approval at the upcoming Annual General Meeting. The dividend, if declared, will be credited/dispatched to eligible shareholders as per the Companies Act, 2013. The board also approved the audited financial results for the year ended March 31, 2026, and the re-appointment of M/s Sanjay Kumar Garg & Associates as Cost Auditor, subject to shareholder ratification.

Titan Biotech Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026. The board recommended a dividend of ₹0.50 per equity share, subject to shareholder approval. They also approved the re-appointment of M/s Sanjay Kumar Garg & Associates as Cost Auditor, pending shareholder ratification. Mr. Pankaj Kumar Gupta was appointed as Scrutinizer for the upcoming Annual General Meeting.

Titan Biotech Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results (standalone and consolidated) for the financial year ended March 31, 2026. The board will also consider recommending a dividend on equity shares, if any. The trading window has been closed from April 1, 2026, and will remain closed until 48 hours after the board meeting outcome.

Titan Biotech Ltd. has announced the launch of the second 100-day campaign under the Saksham Niveshak Yojna, following a circular from the Investor's Education and Protection Fund Authority (IEPFA). The campaign, running from April 1, 2026, to July 9, 2026, aims to create awareness among shareholders to update their details and claim any unpaid or unclaimed dividends before they are transferred to the IEPF. Shareholders are encouraged to update their PAN, nomination details, contact information, and bank account details. The company has provided necessary forms (ISR-1, ISR-2, SH-13, ISR-3) on its website and contact information for queries.

Titan Biotech Ltd has announced the closure of the trading window for dealing in the securities of the company. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct for Prevention of Insider Trading. The closure is effective from Wednesday, 1st April 2026, and will remain in force until 48 hours after the declaration of the audited financial results for the financial year ending on 31st March 2026. The date of the Board Meeting for the approval of these results will be intimated in due course.

Titan Biotech Ltd has announced a 5:1 sub-division/split of its equity shares. The face value of the shares has been reduced from Rs. 10/- to Rs. 2/- each. The sub-divided shares have been credited under new ISIN: INE150C01029 by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). The confirmation letters issued by NSDL and CDSL are enclosed for reference. The corporate action was executed by Beetal Financial & Computer Services Pvt. Ltd, and the shares were credited/debited to the accounts in the NSDL system.